VERNAL KERATOCONJUNCTIVITIS MARKET ANALYSIS

Vernal keratoconjunctivitis (VKC) is an allergic eye disease. It is a multifactorial Th2 cell-mediated ocular surface inflammatory state that primarily affects males, specifically to children. Intense itching, burning, photophobia, and tears are the most common symptoms. The most common signs are conjunctival hyperaemia, superficial keratitis, and giant papillae. The overexpression of mast cells, Th2 cells, cytokines, eosinophils, adhesion molecules, chemokines, and cytokines are characteristics of the vernal keratoconjunctivitis. Limbal infiltration, corneal involvement, conjunctival fibroproliferative lesions, and conjunctival hyperemia are the features of vernal keratoconjunctivitis. Mixed, palpebral, and limbal are the three types of vernal keratoconjunctivitis, which are based on the main anatomical site of the papillary reaction.

The global vernal keratoconjunctivitis market is estimated to be valued at US$ 346.9 million in 2021 and is expected to exhibit a CAGR of 3.6% during the forecast period (2021-2028).

Figure 1.Global Vernal Keratoconjunctivitis Market Value (US$ million), By Region, 2021

To learn more about this report, request sample copy

Key players operating in the global vernal keratoconjuctivities market are focusing on drug approvals, which is anticipated to drive the market growth during the forecast period.

Increasing drug approvals provides the opportunity to provide patients with novel treatment  options, which is projected to boost the market growth during the forecast period. For instance, in June 2021, Santen Pharmaceutical Co., Ltd. announced that U.S. Food and Drug Administration (FDA) approved a new drug verkazia (Cyclosporine Ophthalmic Emulsion, 0.1%) for the treatment of vernal keratoconjunctivitis (VKC) in children as well as adults.

Figure 2.Global Vernal Keratoconjuctivities Market Share (%) in Terms of Value, By Dosage Form, 2021

To learn more about this report, request sample copy

Growing incidences of vernal keratoconjuctivities in young adults and children living in warm environment, is estimated to spur the market growth during the forecast period.

Rising incidences of vernal keratoconjuctivities mainly in young adults and children living in warm environment, is anticipated to boost the market growth during the forecast period. In dark-skinned population from Africa and India, the limbal form of vernal keratoconjunctivities is seen most frequently. For instance, in August 2021, Western Europe incidences were 3.2 in 10,000, whereas in Italy, a country with a Mediterranean climate, a higher prevalence ranging from 2.4 to 27.8 in 10,000 were observed.

Global Vernal Keratoconjunctivitis Market– Impact of Coronavirus (COVID-19) Pandemic

Several clinicians and patients requested better suggestion for the treatment of vernal keratoconjunctivities patients in the COVID-19 pandemic. Most of the patients and doctors were following the recommendations given by scientific societies such as Indian Journal of Ophthalmology. Recently, considering the various difficulties associated with the COVID-19 pandemic, despite the fact that patients require treatments, vernal keratoconjuctivitis has not been prioritised. Topical medicines are the primary line of treatment for types of vernal keratoconjuctivitis with topical corticosteroids added in severe cases of vernal keratoconjunctivitis, even in the patients are at risk of COVID-19.

Global Vernal Keratoconjunctivitis Market: Restraint

There is no precise diagnostic criteria for vernal keratoconjunctivitis, which is anticipated to hamper the market growth during the forecast period. The vernal keratoconjunctivitis disease's distinctive signs and symptoms are used to detect the diagnosis. Several mild or unusual instances may be undetected as no exact diagnostic criteria is been developed.

Key Players

Major players operating in the global vernal keratoconjunctivitis market include Santen, Novartis Pharmaceuticals, Senju Pharmaceutical, Allakos, iCo Therapeutics, and Akari Therapeutics